Sun Pharma stock drops 5% amidst Organon deal buzz and US tariff concerns.

Sun Pharma shares fell 5% on the BSE amid reports of a proposed $12-billion acquisition of Organon &Co. Investors booked profits despite a strong market. Analysts see the acquisition as a mixed bag, citing Organon's debt and competitive pressures in its product segments. US tariff concerns also weigh on the stock.

Sun Pharmaceutical Industries' shares fell 5% on the BSE on April 10, 2026, amid reports that the company is in advanced talks to acquire US-based Organon & Co. for approximately $12 billion, including Organon's existing debt according to market reports. The stock, already under pressure from broader sector concerns and US tariff uncertainties, dropped to around Rs 1,580, nearing its 52-week low of Rs 1,480. Despite a generally strong market, investors remained cautious, with many booking profits as the acquisition speculation intensified.

Organon, a women's health and biosimilars company spun off from Merck in 2021, has been struggling with $8.9 billion in debt and intense competition across its core segments. The company has been actively reducing its debt burden, bringing it down to $8 billion as of 2025. However, its stock has fallen nearly 55% from its November 2024 peak, reflecting ongoing challenges in its business model and governance.

Sun Pharma, which has a near-cash-positive balance sheet with approximately Rs 20,000 crore in reserves, is reportedly arranging financing through multiple global banks to fund the acquisition. If completed, the deal would be the largest global acquisition by an Indian pharma company and could significantly expand Sun Pharma's presence in the US market. However, analysts highlight concerns about the financial implications, including a potential rise in Sun Pharma's net debt-to-EBITDA ratio to 2–2.5x post-deal.

While some analysts argue that Sun Pharma's track record with past acquisitions, such as Taro and Ranbaxy, could justify the risk, others caution that the acquisition could strain the company's balance sheet and integration capabilities. The market remains skeptical, with Sun Pharma officially calling the reports "speculative" in a BSE filing. The next few weeks will be critical in determining whether the deal moves forward and how investors react to the potential transformation of Sun Pharma's business profile.